Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human, multi-center, open-label clinical study with separate dose
escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety,
tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in
participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer
(mCRC), metastatic castration resistant prostate cancer (mCRPC), and higher risk
myelodysplastic syndrome (HR-MDS).
Dose escalation and dose expansion may be included for all parts of the study as determined
by ongoing study results.